nintedanib intravenous solution

BIBF 1120 intravenous solution is an investigational intravenous formulation of nintedanib (formerly known as BIBF 1120), a small-molecule triple angiokinase inhibitor developed by Boehringer Ingelheim. Nintedanib competitively binds to the ATP-binding pocket of vascular endothelial growth factor receptors (VEGFR 1–3), fibroblast growth factor receptors (FGFR 1–3), and platelet-derived growth factor receptors (PDGFR α/β), thereby blocking downstream signaling pathways involved in angiogenesis and fibrogenesis. The intravenous formulation was evaluated in a Phase 1 clinical trial (NCT02182258) to assess its safety, tolerability, and pharmacokinetics, as well as to determine the absolute bioavailability of the oral soft gelatine capsule formulation of nintedanib in healthy male subjects. While the oral capsule formulation of nintedanib is approved for idiopathic pulmonary fibrosis (IPF) and non-small cell lung cancer (NSCLC), the intravenous solution remains an investigational formulation.

Other names

BIBF 1120 intravenousBIBF1120 intravenousBIBF-1120 intravenousBIBF 1120 intravenous solutionBIBF1120 intravenous solutionBIBF-1120 intravenous solutionnintedanib intravenous